TY - JOUR
T1 - TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors
AU - Weigelt, Karin
AU - Carvalho, Livia A.
AU - Drexhage, Roos C.
AU - Wijkhuijs, Annemarie
AU - Wit, Harm de
AU - van Beveren, Nico J.M.
AU - Birkenhäger, Tom K.
AU - Bergink, Veerle
AU - Drexhage, Hemmo A.
N1 - Funding Information:
H.A. Drexhage has received grants from the Netherlands Organisation for Health Research and Development , the European Union , the Stanley Medical Research Institute , the Dutch Diabetic Foundation and the JDRF ; he has served in advisory boards of the Netherlands Organisation for Health Research and Development, the European Union and the JDRF.
Funding Information:
This work was supported by the EU (Health FP7, Nr 222963, Acronym MOODINFLAME), The Dutch Organisation for Research, Medical Sciences (NWO-MW-TOP 08425), the Hersenstichting (15F 07(2)) and an ECNP Young Investigator Award to Livia A. Carvalho.
PY - 2011/8
Y1 - 2011/8
N2 - Introduction: Immune activation is a characteristic of schizophrenia (SCZ), bipolar disorder (BD) and unipolar major depressive disorder (MDD). The triggering receptor expressed on myeloid cells 1 (TREM-1), its' adaptor molecule DAP12 and their transcription factor (TF) PU.1 are important key genes in inflammation and expressed in activated monocytes and microglia. Aim: To test: (1) if the expressions of TREM-1, DAP12 and PU.1 are increased in monocytes of patients with severe psychiatric disorders and (2) if PU.1 and the TFs ATF3 and EGR3 (which have been found as prominent increased monocyte genes in previous studies) are involved in the regulation of TREM-1 and DAP12 expression. Methods: Using Q-PCR, we studied the gene expression of TREM-1, DAP12, PU.1, ATF3 and EGR3 in the monocytes of 73 patients with severe psychiatric disorders (27 recent onset SCZ patients, 22 BD patients and 24 MDD patients) and of 79 healthy controls (HC). Using in silico TF binding site prediction and in vivo chromatin immunoprecipitation (ChIP), we studied the actual binding of EGR3, ATF3 and PU.1 to the promoter regions of TREM-1 and DAP12. Results: 1.TREM-1 gene expression was increased in the monocytes of SCZ and BD patients and tended to be increased in the monocytes of MDD patients.2.DAP12 gene levels were neither increased in the monocytes of SCZ, BD, nor MDD patients.3.PU.1 expression levels were increased in the monocytes of MDD patients, but not in those of SCZ and BD patients.4.TREM-1 expression levels correlated in particular to ATF3 and EGR3 expression levels, DAP12 expression levels correlated in particular to PU.1 expression levels.5.We found using binding site prediction and ChIP assays that the TFs EGR3 and ATF3 indeed bound to the TREM-1 promoter, PU.1 bound to both the TREM-1 and DAP12 promoter. Conclusion: In this study, we provide evidence that TREM-1 gene expression is significantly increased in monocytes of SCZ and BD patients and that the TREM-1 gene is a target gene of the TFs ATF3 and EGR3. In MDD patients, PU.1 gene expression was increased with a tendency for TREM-1 gene over expression. Our observations support the concept that monocytes are in a pro-inflammatory state in severe psychiatric conditions and suggest differences in monocyte inflammatory set points between SCZ, BD and MDD.
AB - Introduction: Immune activation is a characteristic of schizophrenia (SCZ), bipolar disorder (BD) and unipolar major depressive disorder (MDD). The triggering receptor expressed on myeloid cells 1 (TREM-1), its' adaptor molecule DAP12 and their transcription factor (TF) PU.1 are important key genes in inflammation and expressed in activated monocytes and microglia. Aim: To test: (1) if the expressions of TREM-1, DAP12 and PU.1 are increased in monocytes of patients with severe psychiatric disorders and (2) if PU.1 and the TFs ATF3 and EGR3 (which have been found as prominent increased monocyte genes in previous studies) are involved in the regulation of TREM-1 and DAP12 expression. Methods: Using Q-PCR, we studied the gene expression of TREM-1, DAP12, PU.1, ATF3 and EGR3 in the monocytes of 73 patients with severe psychiatric disorders (27 recent onset SCZ patients, 22 BD patients and 24 MDD patients) and of 79 healthy controls (HC). Using in silico TF binding site prediction and in vivo chromatin immunoprecipitation (ChIP), we studied the actual binding of EGR3, ATF3 and PU.1 to the promoter regions of TREM-1 and DAP12. Results: 1.TREM-1 gene expression was increased in the monocytes of SCZ and BD patients and tended to be increased in the monocytes of MDD patients.2.DAP12 gene levels were neither increased in the monocytes of SCZ, BD, nor MDD patients.3.PU.1 expression levels were increased in the monocytes of MDD patients, but not in those of SCZ and BD patients.4.TREM-1 expression levels correlated in particular to ATF3 and EGR3 expression levels, DAP12 expression levels correlated in particular to PU.1 expression levels.5.We found using binding site prediction and ChIP assays that the TFs EGR3 and ATF3 indeed bound to the TREM-1 promoter, PU.1 bound to both the TREM-1 and DAP12 promoter. Conclusion: In this study, we provide evidence that TREM-1 gene expression is significantly increased in monocytes of SCZ and BD patients and that the TREM-1 gene is a target gene of the TFs ATF3 and EGR3. In MDD patients, PU.1 gene expression was increased with a tendency for TREM-1 gene over expression. Our observations support the concept that monocytes are in a pro-inflammatory state in severe psychiatric conditions and suggest differences in monocyte inflammatory set points between SCZ, BD and MDD.
KW - ATF3
KW - EGR3
KW - Inflammation
KW - Monocytes
KW - Psychiatry
KW - TREM-1
UR - http://www.scopus.com/inward/record.url?scp=79960242993&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2011.03.006
DO - 10.1016/j.bbi.2011.03.006
M3 - Article
C2 - 21421043
AN - SCOPUS:79960242993
SN - 0889-1591
VL - 25
SP - 1162
EP - 1169
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
IS - 6
ER -